ALLR · Allarity Therapeutics, Inc.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $320K | $0 | — | — | — | — | |
| — | — | — | — | — | -$1.35M | — | |
| — | — | — | — | -$2.27M | — | — | |
| $5.52M | $6.6M | $6.1M | $7.1M | $6.93M | $14.2M | $4.22M | |
| $5.62M | $6.32M | $11.44M | $10.03M | $9.96M | $12.36M | $4.1M | |
| $29K | — | $9000 | $37K | $60K | $106K | $46K | |
| $11.14M | $12.93M | $27.24M | $17.13M | $34.46M | $26.56M | $8.32M | |
| -$10.8M | -$12.61M | -$27.24M | -$17.13M | -$34.46M | -$26.56M | -$8.32M | |
| — | -3939.06% | — | — | — | — | — | |
| -$26.77M | — | -$27.23M | -$17.09M | -$34.4M | -$26.45M | -$8.27M | |
| $1.06M | $185K | $653K | $498K | $223K | — | $93K | |
| $722K | $801K | $533K | $22K | $30K | — | — | |
| -$1.54M | $1.37M | $2.35M | $5.31M | $16.88M | $41K | $1.9M | |
| — | — | — | — | -$115K | -$495K | $708K | |
| — | -$11.23M | -$24.9M | -$11.82M | -$17.58M | — | — | |
| — | $0 | -$381K | $83K | -$1.52M | $133K | $198K | |
| -$12.33M | -$11.23M | -$24.52M | -$11.9M | -$16.06M | -$26.65M | -$6.62M | |
| — | -3509.69% | — | — | — | — | — | |
| — | — | — | — | — | — | -$15K | |
| — | -$11.23M | -$25.15M | -$20.42M | -$21.05M | -$26.65M | -$6.62M | |
| -$11.22M | -$11.9M | -$24.46M | -$11.59M | -$16.18M | -$28.62M | -$4.14M | |
| USD/shares | -$0.76 | -$0.78 | -$15.65 | -$6,031.31 | -$1,856,052.00 | -$3,519,600.00 | -$1,705,200.00 |
| USD/shares | $199,624.20 | — | — | -$6,156.00 | -$1,856,052.00 | -$3,519,600.00 | — |
| shares | — | 14.38M | 1.61M | 3385 | 11.3417 | 7.5702 | 3.8866 |
| shares | — | — | — | 3317.9133 | 11.3417 | 7.5702 | 3.8866 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $3.19M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 238 similar-size Biotechnology companies (of 514 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| License | $320,000 | $0 |